Selective laser trabeculoplasty versus eye drops for first line treatment of exfoliation ocular hypertension or glaucoma: a randomised clinical trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520083-33-00

Enrollment

112

Registered

2024-12-19

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Brief summary

Primary end point is acceleration of the treatment by adding eye drops.

Detailed description

Secondary end points are eye dryness and eye pressure and long term end points are cumulative success of SLT-treatment and need for glaucoma surgery.

Interventions

DRUGTaflotan® 15 mikrogrammaa/ml silmätipat

DRUGliuos kerta-annospipetissä

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Primary end point is acceleration of the treatment by adding eye drops.	—

Secondary

Measure	Time frame
Secondary end points are eye dryness and eye pressure and long term end points are cumulative success of SLT-treatment and need for glaucoma surgery.	—

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026